Targeting tumor-associated macrophages to synergize tumor immunotherapy

X Xiang, J Wang, D Lu, X Xu - Signal transduction and targeted therapy, 2021 - nature.com
The current treatment strategies in advanced malignancies remain limited. Notably,
immunotherapies have raised hope for a successful control of these advanced diseases, but …

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

W Zou, JD Wolchok, L Chen - Science translational medicine, 2016 - science.org
Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a …

Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors

D Dangaj, M Bruand, AJ Grimm, C Ronet, D Barras… - Cancer cell, 2019 - cell.com
We investigated the role of chemokines in regulating T cell accumulation in solid tumors.
CCL5 and CXCL9 overexpression was associated with CD8+ T cell infiltration in solid …

Apigenin in cancer therapy: Anti-cancer effects and mechanisms of action

X Yan, M Qi, P Li, Y Zhan, H Shao - Cell & bioscience, 2017 - Springer
Apigenin is a common dietary flavonoid that is abundantly present in many fruits, vegetables
and Chinese medicinal herbs and serves multiple physiological functions, such as strong …

Immune checkpoints and their inhibition in cancer and infectious diseases

L Dyck, KHG Mills - European journal of immunology, 2017 - Wiley Online Library
The development of chronic infections and cancer is facilitated by a variety of immune
subversion mechanisms, such as the production of anti‐inflammatory cytokines, induction of …

Epigenetic control of CD8+ T cell differentiation

AN Henning, R Roychoudhuri, NP Restifo - Nature Reviews …, 2018 - nature.com
Upon stimulation, small numbers of naive CD8+ T cells proliferate and differentiate into a
variety of memory and effector cell types. CD8+ T cells can persist for years and kill tumour …

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria… - Nature reviews …, 2015 - nature.com
High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

Tumor-associated macrophages: from mechanisms to therapy

R Noy, JW Pollard - Immunity, 2014 - cell.com
The tumor microenvironment is a complex ecology of cells that evolves with and provides
support to tumor cells during the transition to malignancy. Among the innate and adaptive …

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

L Deng, H Liang, B Burnette, M Beckett… - The Journal of …, 2014 - Am Soc Clin Investig
High-dose ionizing irradiation (IR) results in direct tumor cell death and augments tumor-
specific immunity, which enhances tumor control both locally and distantly. Unfortunately …

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

S Ugel, F De Sanctis, S Mandruzzato… - The Journal of clinical …, 2015 - Am Soc Clin Investig
The generation of an inflammatory environment is favorable and often decisive for the
growth of both primary tumors and metastases. Tumor cells either express membrane …